secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0000950170-25-072931
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longevity Health Q1 pro forma sales $663k, merger with 20/20 BioLabs progressing
--------------------------------------------------------------------------------

- XAGE Q1 unaudited pro forma sales ~$663k (+8% YoY); 20/20 sales ~$562k (+15% YoY).
- Merger agreement with 20/20 signed April 11; S-4 filed May 8; closing subject to conditions.
- 1-for-30 reverse stock split completed May 12; trading at split-adjusted price from May 14.
- Expected Q2 launches: XAGE medicated cleanser, 20/20 inflammatory biomarker test, and OneTest pilot with Giant Food.
- Company evaluating options for additional financing, anticipates primary investment in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000095017025072931/0000950170-25-072931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000095017025072931/xage-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-072931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer